Available as injections or oral tablets
10.1007/s11064-019-02838-w Neurochem
There were 206 participants in PIONEER 6 from India
Expanding Capabilities in High-Growth Segment The move comes as Gland Pharma positions itself to capitalize on the growing demand for GLP-1 (glucagon-like peptide-1) products, which are increasingly used in the treatment of type 2 diabetes and obesity
Further experiments by Park et al
This data offers meaningful proof that a structured, clinically integrated GLP-1 strategy can deliver millions in real savings without compromising access or member outcomes.* Employer health strategies have traditionally centered on condition-specific programs to manage diseases like obesity, diabetes, and cardiovascular conditions individually, which has led to employers managing multiple point solutions simultaneously, often with low coordination, engagement, and return on investment